Chemotherapy Research and Practice

Chemotherapy Research and Practice / 2020 / Article

Corrigendum | Open Access

Volume 2020 |Article ID 1375374 | https://doi.org/10.1155/2020/1375374

Nida Iqbal, Naveed Iqbal, "Corrigendum to “Imatinib: A Breakthrough of Targeted Therapy in Cancer”", Chemotherapy Research and Practice, vol. 2020, Article ID 1375374, 1 page, 2020. https://doi.org/10.1155/2020/1375374

Corrigendum to “Imatinib: A Breakthrough of Targeted Therapy in Cancer”

Received15 Sep 2020
Accepted15 Sep 2020
Published28 Dec 2020

The article titled “Imatinib: A Breakthrough of Targeted Therapy in Cancer” [1] was found to contain material from previously published work, mainly in sections 3.1, 3.3, 3.4, 3.5, and 3.6. The articles are as follows:(i)S. A. Khan, “Targeted therapies for philadelphia chromosome-positive acute lymphoblastic leukemia,” School of Pharmacy, 37, 5 (Oncology suppl): 3–7, 2012 (https://www.uspharmacist.com/article/targeted-therapies-for-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia) [2] (not cited).(ii)A. Olivieri, M. Cimminiello, P. Corradini, et al., “Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD,” Blood, 2013, doi: https://doi.org/10.1182/blood-2013-05-494278 (http://www.bloodjournal.org/content/122/25/4111) [3] (cited as reference 56).(iii)C. Ustun, D. L. DeRemer, and C. Akin, “Tyrosine kinase inhibitors in the treatment of systemic mastocytosis,” Leukemia Research, 2011, doi: https://doi.org/10.1016/j.leukres.2011.05.006 (https://www.lrjournal.com/article/S0145-2126(11)00223-2/fulltext) [4] (not cited).(iv)S. Verstovsek, “New Hematological Indications for Imatinib,” Hematological Cancer, 2007, doi: http://doi.org/10.17925/OHR.2007.00.2.36 (https://www.touchoncology.com/articles/new-hematological-indications-imatinib) [5] (not cited).(v)M. Breccia and G. Alimena, “Resistance to Imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem,” Cardiovascular and Hematological Disorders-Drug Targets, 2009, doi: https://doi.org/10.2174/187152909787581363 (http://www.eurekaselect.com/68887/article) [6] (not cited).

References

  1. N. Iqbal and N. Iqbal, “Imatinib: a breakthrough of targeted therapy in cancer,” Chemotherapy Research and Practice, vol. 2014, Article ID 357027, 9 pages, 2014. View at: Publisher Site | Google Scholar
  2. S. A. Khan, “Targeted therapies for philadelphia chromosome-positive acute lymphoblastic leukemia,” School of Pharmacy, vol. 37, no. Oncology suppl, pp. 3–7, 2012. View at: Google Scholar
  3. A. Olivieri, M. Cimminiello, P. Corradini et al., “Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD,” Blood, vol. 122, no. 25, pp. 4111–4118, 2013. View at: Publisher Site | Google Scholar
  4. C. Ustun, D. L. DeRemer, and C. Akin, “Tyrosine kinase inhibitors in the treatment of systemic mastocytosis,” Leukemia Research, vol. 35, no. 9, pp. 1143–1152, 2011. View at: Publisher Site | Google Scholar
  5. S. Verstovsek, “New hematological indications for Imatinib,” Oncology & Hematology Review (US), vol. 1, no. 2, pp. 36–39, 2007. View at: Publisher Site | Google Scholar
  6. M. Breccia and G. Alimena, “Resistance to Imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem,” Cardiovascular & Hematological Disorders-Drug Targets, vol. 9, no. 1, pp. 21–28, 2009. View at: Publisher Site | Google Scholar

Copyright © 2020 Nida Iqbal and Naveed Iqbal. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views68
Downloads0
Citations

Related articles